MCID: MLR006
MIFTS: 40

Male Reproductive Organ Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Male Reproductive Organ Cancer

MalaCards integrated aliases for Male Reproductive Organ Cancer:

Name: Male Reproductive Organ Cancer 12 15 17
Genital Neoplasms, Male 43 71
Malignant Neoplasm of Male Genital Organ or Tract 12
Malignant Tumor of Male Reproductive System 12
Malignant Neoplasm of Male Genital Organs 12
Malignant Neoplasm of Male Genital Organ 12
Malignant Tumor of Male Genital Organ 12
Male Reproductive System Neoplasm 12
Tumor of Male Reproductive System 12
Neoplasm of Male Genital Organ 12
Male Genital Neoplasm 12
Male Genital Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3856
ICD9CM 34 187.9
MeSH 43 D005834
NCIt 49 C3054 C8561
SNOMED-CT 67 93885006
UMLS 71 C0017417 C0153606

Summaries for Male Reproductive Organ Cancer

Disease Ontology : 12 A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.

MalaCards based summary : Male Reproductive Organ Cancer, also known as genital neoplasms, male, is related to prostate cancer and seminal vesicle adenocarcinoma. An important gene associated with Male Reproductive Organ Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Neostigmine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and thyroid.

Related Diseases for Male Reproductive Organ Cancer

Diseases related to Male Reproductive Organ Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 33.1 SERPINA3 MIR34A MIR30A MIR222 MIR221 MIR21
2 seminal vesicle adenocarcinoma 11.3
3 littre gland carcinoma 11.3
4 cowper gland carcinoma 11.3
5 ovary epithelial cancer 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR17 MIR145
6 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR17 MIR145
7 endocrine organ benign neoplasm 10.9 SERPINA3 MIR221 MIR21 MIR199A1 MIR17 MIR126
8 biliary tract disease 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR199A1 MIR17
9 intestinal benign neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR15A MIR143
10 disease of mental health 10.9 SERPINA3 MIR9-1 MIR30A MIR21 MIR199A1 MIR17
11 bile duct disease 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR199A1 MIR17
12 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR15A MIR143
13 mouth disease 10.9 SERPINA3 MIR9-1 MIR221 MIR21 MIR199A1 MIR17
14 ovarian serous carcinoma 10.9 MIR21 MIR199A1 MIR145 MIR143 MIR141 MIR125A
15 inherited metabolic disorder 10.9 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
16 oral cavity cancer 10.9 SERPINA3 MIR9-1 MIR574 MIR30A MIR21 MIR199A1
17 gallbladder disease 10.9 SERPINA3 MIR222 MIR199A1 MIR17 MIR145 MIR143
18 cell type benign neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR143 MIR126
19 lymphatic system cancer 10.9 SERPINA3 MIR17 MIR126 KDM4C H2AC18
20 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.9 SERPINA3 MIR9-1 MIR199A1 MIR17 KDM4C H2AC18
21 mature b-cell neoplasm 10.9 MIR9-1 MIR222 MIR199A1 MIR17 KDM4C H2AC18
22 autosomal genetic disease 10.9 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
23 cerebral arterial disease 10.9 SERPINA3 MIR145 MIR143 MIR126 MIR125A
24 upper respiratory tract disease 10.9 SERPINA3 MIR9-1 MIR574 MIR30A MIR21 MIR199A1
25 aortic valve disease 2 10.9 SERPINA3 MIR34A MIR21 MIR199A1 MIR17 MIR126
26 retinal cancer 10.9 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C H2AC18
27 diffuse large b-cell lymphoma 10.9 MIR222 MIR221 MIR21 MIR199A1 MIR17 MIR145
28 bile duct adenocarcinoma 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR125A
29 muscle cancer 10.9 SERPINA3 MIR9-1 MIR199A1 MIR143 H2AC18
30 tongue disease 10.9 MIR574 MIR30A MIR21 MIR199A1 MIR17 MIR145
31 bone marrow cancer 10.9 MIR9-1 MIR34A MIR30A MIR21 MIR199A1 MIR17
32 ocular cancer 10.9 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C H2AC18
33 glucose metabolism disease 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR21 MIR199A1
34 connective tissue cancer 10.9 SERPINA3 MIR9-1 MIR574 MIR222 MIR21 MIR199A1
35 bronchial disease 10.9 SERPINA3 MIR21 MIR17 MIR126 H2AC18
36 immune system disease 10.9 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR21
37 thyroid gland disease 10.9 MIR9-1 MIR574 MIR30A MIR222 MIR221 MIR21
38 lymphatic system disease 10.9 SERPINA3 MIR17 MIR125A KDM4C H2AC18
39 cardiovascular system disease 10.9 SERPINA3 MIR34A MIR21 MIR199A1 MIR17 MIR145
40 polymyositis 10.9 MIR30A MIR222 MIR221 MIR21
41 pancreatic ductal adenocarcinoma 10.9 MIR222 MIR221 MIR21 MIR199A1 MIR15A MIR145
42 testicular disease 10.9 SERPINA3 MIR199A1 KDM4C H2AC18
43 muscle tissue disease 10.9 SERPINA3 MIR9-1 MIR221 MIR199A1 H2AC18
44 retinal vascular disease 10.9 MIR30A MIR21 MIR199A1 MIR126 H2AC18
45 bone inflammation disease 10.9 SERPINA3 MIR34A MIR30A MIR21 MIR199A1 MIR17
46 central nervous system disease 10.9 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR21
47 oral squamous cell carcinoma 10.9 MIR9-1 MIR34A MIR221 MIR21 MIR199A1 MIR17
48 coronary heart disease 1 10.9 MIR222 MIR221 MIR182 MIR17 MIR145 MIR126
49 autoimmune disease of musculoskeletal system 10.9 SERPINA3 MIR34A MIR30A MIR221 MIR21 MIR125A
50 overnutrition 10.9 SERPINA3 MIR9-1 MIR34A MIR222 MIR21 MIR199A1

Graphical network of the top 20 diseases related to Male Reproductive Organ Cancer:



Diseases related to Male Reproductive Organ Cancer

Symptoms & Phenotypes for Male Reproductive Organ Cancer

Drugs & Therapeutics for Male Reproductive Organ Cancer

Drugs for Male Reproductive Organ Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
2 Neurotransmitter Agents Phase 4
3 Autonomic Agents Phase 4
4 Cholinergic Agents Phase 4
5 Cholinesterase Inhibitors Phase 4
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
9
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
10
Clonidine Approved Phase 3 4205-90-7 2803
11
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
12
Racepinephrine Approved Phase 3 329-65-7 838
13 Hormone Antagonists Phase 3
14 Hormones Phase 3
15 Central Nervous System Depressants Phase 3
16 Gastrointestinal Agents Phase 3
17 Antiemetics Phase 3
18 Anti-Inflammatory Agents Phase 3
19 Antineoplastic Agents, Hormonal Phase 3
20 glucocorticoids Phase 3
21 Analgesics Phase 3
22 Anesthetics, Local Phase 3
23 Anesthetics Phase 3
24 Antihypertensive Agents Phase 3
25 Sympathomimetics Phase 3
26 Epinephryl borate Phase 3
27 HIV Protease Inhibitors Phase 3
28
protease inhibitors Phase 3
29 Adrenergic Agonists Phase 3
30 Respiratory System Agents Phase 3
31 Anti-Asthmatic Agents Phase 3
32 Adrenergic alpha-2 Receptor Agonists Phase 3
33 Vasoconstrictor Agents Phase 3
34 Anesthetics, General Phase 3
35 Adrenergic beta-Agonists Phase 3
36 BB 1101 Phase 3
37 Anesthetics, Intravenous Phase 3
38 Hypnotics and Sedatives Phase 3
39 Bronchodilator Agents Phase 3
40 Mydriatics Phase 3
41 Sympatholytics Phase 3
42 Adrenergic Agents Phase 3
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
45
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
46
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
47
Pembrolizumab Approved Phase 2 1374853-91-4
48 Onapristone Investigational Phase 1, Phase 2 96346-61-1
49 Bombesin Investigational Phase 1, Phase 2 31362-50-2
50 Imatinib Mesylate Phase 2 220127-57-1 123596

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 The Effect of Deep Neuromuscular Blockade With Sugammadex Reversal on Shoulder Pain of Elderly Patients Undergoing Robotic Surgery: A Single-Center Double-Blinded Randomized Controlled Trial Active, not recruiting NCT03210376 Phase 4 Deep Neuromuscular Blockade (NMB);Moderate Neuromuscular Blockade (NMB);Sugammadex;Neostigmine
2 Prospective Randomized Clinical Trial to Evaluate the Use of Caudal Nerve Blocks in Adult Penile Prosthesis Surgery Recruiting NCT02740127 Phase 3 Ropivacaine;Epinephrine;Decadron;Clonidine;Propofol
3 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
4 Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin Completed NCT00210041 Phase 2 Gemcitabine;Cisplatin
5 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
6 Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate Completed NCT01540994 Phase 1, Phase 2
7 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
8 A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy Completed NCT01431391 Phase 2 leuprolide acetate
9 A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206 Terminated NCT02499952 Phase 2 Pembrolizumab
10 An Open-label, Multi Center PET/CT Study for Investigation of Safety and Diagnostic Performance of the 68Ga Labeled PET Tracer [68Ga]RM2 in Patients With Primary Prostate Cancer Terminated NCT02483884 Phase 1, Phase 2 [68Ga]RM2
11 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
12 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
13 A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy Withdrawn NCT03035357 Phase 2 Daratumumab
14 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
15 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
16 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
17 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
18 Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
19 Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance Recruiting NCT03162627 Phase 1 Selumetinib;Olaparib
20 A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors Recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
21 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
22 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
23 A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn NCT02812056 Phase 1 Alisertib;TAK-228
24 An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy Approved for marketing NCT01217697 Abiraterone Acetate;Prednisone\Prednisolone
25 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
26 Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging. Recruiting NCT02319239
27 Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial Recruiting NCT02464696
28 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
29 Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14) Active, not recruiting NCT02192333
30 Protection of Rectum From High Radiation Doses During Prostate Cancer Low-dose Brachytherapy Using Diluted or Non-diluted DuraSeal as a Spacer Terminated NCT01918605

Search NIH Clinical Center for Male Reproductive Organ Cancer

Cochrane evidence based reviews: genital neoplasms, male

Genetic Tests for Male Reproductive Organ Cancer

Anatomical Context for Male Reproductive Organ Cancer

MalaCards organs/tissues related to Male Reproductive Organ Cancer:

40
Prostate, Bone, Thyroid, Breast, Heart, Colon, Ovary

Publications for Male Reproductive Organ Cancer

Articles related to Male Reproductive Organ Cancer:

(show all 13)
# Title Authors PMID Year
1
Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival. 61
30418430 2019
2
Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 61
26586684 2015
3
Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. 61
26421823 2015
4
Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 61
24653502 2012
5
Obesity and familial obesity and risk of cancer. 61
21606843 2011
6
Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. 61
21868477 2011
7
Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. 61
20151937 2010
8
Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994-2003. 61
18667299 2008
9
Assessment of outcomes at alternative medicine cancer clinics: a feasibility study. 61
11246933 2001
10
Male genital cancers. 61
9628963 1998
11
[Radiation injuries of the small intestine. Surgical treatment]. 61
8758520 1996
12
Male genital cancers. 61
8001002 1995
13
[Hormone therapy of male genital cancer (prostatic cancer)]. 61
2444164 1987

Variations for Male Reproductive Organ Cancer

Expression for Male Reproductive Organ Cancer

Search GEO for disease gene expression data for Male Reproductive Organ Cancer.

Pathways for Male Reproductive Organ Cancer

Pathways related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.96 MIR9-1 MIR34A MIR30A MIR222 MIR221 MIR21
2 11.03 MIR222 MIR221 MIR145
3 10.84 MIR9-1 MIR222 MIR221 MIR199A1
4 10.37 MIR199A1 MIR145

GO Terms for Male Reproductive Organ Cancer

Cellular components related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 SERPINA3 MIR574 MIR30A MIR222 MIR221 MIR21

Biological processes related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 MIR34A MIR30A MIR21 MIR182 MIR125A KDM4C
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 MIR222 MIR221 MIR21 MIR126
3 positive regulation of angiogenesis GO:0045766 9.88 MIR30A MIR21 MIR199A1 MIR143 MIR126
4 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.8 MIR30A MIR222 MIR221
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 MIR222 MIR221 MIR21
6 negative regulation of inflammatory response GO:0050728 9.8 MIR222 MIR221 MIR15A MIR141 MIR126
7 positive regulation of protein kinase B signaling GO:0051897 9.8 MIR222 MIR221 MIR21 MIR199A1 MIR143 MIR126
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.78 MIR34A MIR182 MIR15A
9 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.77 MIR21 MIR199A1 MIR145
10 negative regulation of sprouting angiogenesis GO:1903671 9.77 MIR34A MIR221 MIR17
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR222 MIR221 MIR21 MIR17
12 negative regulation of angiogenesis GO:0016525 9.76 MIR34A MIR222 MIR21 MIR15A MIR145 MIR143
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.73 MIR221 MIR21 MIR143
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR30A MIR221 MIR143 MIR126
15 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.68 MIR34A MIR17
16 negative regulation of cardiac muscle hypertrophy GO:0010614 9.68 MIR21 MIR145
17 regulation of smooth muscle contraction GO:0006940 9.67 MIR145 MIR143
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR199A1 MIR17
19 positive regulation of connective tissue replacement GO:1905205 9.67 MIR34A MIR199A1
20 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.66 MIR199A1 MIR17
21 positive regulation of axon regeneration GO:0048680 9.66 MIR222 MIR221
22 positive regulation of metalloendopeptidase activity GO:1904685 9.65 MIR21 MIR17
23 negative regulation by host of viral genome replication GO:0044828 9.65 MIR222 MIR221
24 angiotensin-activated signaling pathway GO:0038166 9.65 MIR145 MIR143
25 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.64 MIR21 MIR17
26 aorta smooth muscle tissue morphogenesis GO:0060414 9.63 MIR145 MIR143
27 regulation of phenotypic switching GO:1900239 9.62 MIR145 MIR143
28 negative regulation of cell adhesion molecule production GO:0060354 9.61 MIR222 MIR221
29 miRNA mediated inhibition of translation GO:0035278 9.61 MIR9-1 MIR30A MIR222 MIR221 MIR21 MIR182
30 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.58 MIR17 MIR143
31 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.58 MIR222 MIR221
32 positive regulation of Schwann cell migration GO:1900149 9.57 MIR222 MIR221
33 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR34A MIR21 MIR182 MIR15A
34 negative regulation of vascular smooth muscle cell dedifferentiation GO:1905175 9.55 MIR182 MIR145
35 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.54 MIR222 MIR221
36 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR222 MIR221 MIR141
37 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.52 MIR222 MIR221
38 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.51 MIR145 MIR143
39 gene silencing by miRNA GO:0035195 9.5 MIR9-1 MIR34A MIR30A MIR222 MIR221 MIR21

Molecular functions related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR34A MIR30A MIR222 MIR221 MIR21
2 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A

Sources for Male Reproductive Organ Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....